Mylan Rejects Teva's $40 Billion Takeover Offer - The New York Times
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Mylan/Viatris and Teva at the 38th Annual J.P. Morgan Healthcare Conference - MidgardFinance.com
Teva seeks cushion against loss of patent protection | Financial Times
Mylan-Pfizer off-patent merger boosts Teva - Globes
Look out, Teva: Mylan's Copaxone copy has already captured serious share | Fierce Pharma
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Israel's Teva drops bid for Mylan, buys Allergan for $40.5B | TribLIVE.com
Teva says Actavis Closing on Track | CHEManager
Teva bid for Mylan sparks worries of rising generic drug prices - The Economic Times
Mylan plays monkey-in-the-middle of hostile takeover battles | Fortune
Mylan says merger with Teva would be bad fit | Reuters
Teva offers to buy Mylan for $40.1 billion - The Economic Times
Mylan board rejects Teva takeover bid
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Brief M&A: MergerTalk: Pfizer/Mylan -Don't Overdose on the Sector, but Mylan Over Teva Pair Trade Is Still On and more | Smartkarma
$40B deal: Teva offers to buy Mylan
Mylan rejects Teva's $40 bn offer as 'gross undervaluation' | The Financial Express
